Key Takeaways: The Dotanoc PET scan (68Ga Dotanoc PET/CT) is the gold standard imaging investigation for neuroendocrine tumours (NETs), delivering sensitivity and specificity that far exceeds all previous imaging methods. It is essential for staging, PRRT patient selection, and treatment monitoring. Neurad Diagnostics provides daily 68Ga Dotanoc PET/CT via its in-house Gallium Generator, with expert nuclear medicine reporting specifically tailored to the multidisciplinary NET team.
Dotanoc PET Scan: The Gold Standard in Neuroendocrine Tumour Imaging
The Dotanoc PET scan — formally known as 68Ga-DOTA-NOC PET/CT — is a somatostatin receptor-targeting nuclear medicine imaging investigation that has become the unambiguous gold standard for the evaluation of neuroendocrine tumours (NETs). It achieves this status by combining the molecular targeting precision of somatostatin receptor scintigraphy with the superior resolution, speed, and quantitative capability of modern PET/CT technology. The result is an imaging modality that detects NET lesions — including primary tumours, lymph node metastases, hepatic metastases, and distant metastases — with sensitivity and specificity that consistently exceed 90% in well-designed prospective clinical trials.
Neuroendocrine tumours are a heterogeneous group of neoplasms arising from cells of the diffuse neuroendocrine system. They can occur virtually anywhere in the body, but are most common in the gastrointestinal tract (small intestine, ileum, appendix, colon, rectum), the pancreas, and the lungs. Their clinical behaviour ranges from indolent, slow-growing tumours that may be managed with watchful waiting or somatostatin analogues, to aggressive poorly differentiated neuroendocrine carcinomas requiring platinum-based chemotherapy. Accurate staging and biological characterisation via Dotanoc PET scan is the essential foundation for selecting the appropriate management strategy.
Neurad Diagnostics provides daily Dotanoc PET/CT through our in-house 68Ga Gallium Generator. This means our patients — and the oncologists, gastroenterologists, and endocrinologists who refer them — never face the supply chain delays and booking backlogs that plague centres dependent on external radiopharmaceutical delivery. Our dedicated NET imaging programme is supported by nuclear medicine physicians with subspecialty expertise in somatostatin receptor imaging.
How Does the Dotanoc PET Scan Work? The Somatostatin Receptor Pathway Explained
The targeting mechanism of the Dotanoc PET scan exploits one of the defining biological characteristics of neuroendocrine tumours: the overexpression of somatostatin receptors (SSTRs) on their cell surface. There are five known subtypes of somatostatin receptor (SSTR1–5), and well-differentiated NETs characteristically overexpress SSTR2, SSTR3, and SSTR5. The DOTA-NOC peptide in the Dotanoc radiopharmaceutical is a synthetic somatostatin analogue with high binding affinity for all three of these subtypes — giving it a broader binding profile than the earlier DOTATATE compound (which binds predominantly to SSTR2).
When 68Ga-DOTA-NOC is injected intravenously, it circulates in the bloodstream and binds to SSTR-overexpressing NET cells throughout the body. The bound gallium-68 undergoes positron emission, which is detected by the PET scanner to produce a three-dimensional map of SSTR expression — directly corresponding to NET tumour burden. The simultaneously acquired CT provides the anatomical context, resulting in a fused PET/CT image that shows precisely where each NET lesion is located, how large it is, and how intensely it expresses somatostatin receptors. This last point is particularly important: quantitative SSTR expression (measured as maximum standardised uptake value, or SUVmax) directly predicts whether the patient is likely to respond to PRRT with 177Lu-DOTATATE.
Dotanoc PET Scan Indications: Who Needs This Investigation?
Initial Staging of Confirmed or Suspected Neuroendocrine Tumours
For any patient with a histologically confirmed NET diagnosis, Dotanoc PET scan is the mandatory first-line staging investigation. It maps the full extent of disease — from primary tumour through regional lymph nodes and hepatic metastases to bone and other distant sites — in a single whole-body examination. This comprehensive staging directly determines treatment eligibility: resectability of the primary tumour, suitability for PRRT, and the appropriateness of somatostatin analogue therapy as the primary management.
Detection of Unknown Primary in Suspected NET
A clinically important and technically challenging scenario is the patient who presents with liver metastases or elevated serum biomarkers (chromogranin A, 5-HIAA) strongly suggestive of a NET, but where the primary tumour location is unknown. Conventional CT and MRI frequently fail to identify the primary in this scenario — particularly small intestinal primaries that can be as small as 5mm yet drive extensive hepatic metastatic disease. Dotanoc PET scan detects the primary in 60–80% of cases where conventional imaging fails, dramatically changing the surgical and medical management plan.
Patient Selection for PRRT (Peptide Receptor Radionuclide Therapy)
PRRT with 177Lu-DOTATATE (Lutathera) is one of the most effective treatments for advanced, progressive, well-differentiated gastroenteropancreatic NETs. Its efficacy is entirely dependent on the tumour expressing adequate levels of SSTR2 — and Dotanoc PET scan quantification is the accepted biomarker for PRRT eligibility. The Krenning scale and SUVmax thresholds established from Dotanoc PET/CT data guide PRRT centres worldwide in selecting patients likely to achieve durable disease control from this therapy. Neurad Diagnostics PRRT-planning Dotanoc PET/CT reports explicitly include SUVmax quantification and Krenning scale equivalence to facilitate this selection process.
Restaging After Treatment
Dotanoc PET scan is used to assess treatment response and detect disease progression after surgery, PRRT, ablation, or somatostatin analogue therapy. The ability to compare quantitative SSTR expression (SUVmax) between pre- and post-treatment scans provides objective, tumour-biology-based evidence of response — superior to anatomical measurements alone. Emerging criteria for PRRT response assessment based on Dotanoc PET/CT metrics are increasingly adopted in clinical practice and NET clinical trials.
Evaluation of Related Tumour Types
Beyond gastroenteropancreatic NETs, Dotanoc PET scan is also valuable for: phaeochromocytoma and paraganglioma (PPGL) — particularly for metastatic PPGL where SSTR2 expression is common; medullary thyroid carcinoma staging and restaging; Merkel cell carcinoma; pulmonary carcinoid tumours; and selected meningiomas, which also express SSTRs. Neurad Diagnostics has experience in all these less common indications and our reporting team provides clinically contextualised interpretation for each specific tumour type.
Dotanoc vs. Dotatate vs. Dotatoc: Which Is Best?
A common question from referring clinicians concerns the choice between the three main 68Ga-DOTA-peptide compounds: DOTA-NOC (Dotanoc), DOTA-TATE (Dotatate), and DOTA-TOC (Dotatoc). All three are somatostatin analogues with excellent clinical performance for NET imaging. The key differences lie in their receptor binding profiles: DOTATATE binds predominantly to SSTR2; DOTATOC binds SSTR2 and SSTR5; and DOTA-NOC binds SSTR2, SSTR3, and SSTR5, giving the broadest receptor coverage.
In head-to-head comparison studies, the differences in diagnostic performance between these three compounds are modest and may not be clinically significant in most cases. The choice in clinical practice is often determined by local availability and institutional expertise. At Neurad Diagnostics, we offer 68Ga Dotanoc as our preferred NET imaging agent given its broader receptor binding profile and extensive clinical evidence base. Our nuclear medicine team can discuss the optimal choice for specific clinical scenarios, particularly for tumours with known differential receptor expression profiles. [Insert External Link to Comparative review of DOTA-peptides, EJNMMI research, PubMed]
Preparing for Your Dotanoc PET Scan at Neurad Diagnostics
Preparation for Dotanoc PET scan includes specific considerations related to somatostatin analogue therapy that distinguish it from other 68Ga scans. Our team provides detailed written instructions at the time of booking, but the following overview covers the most important preparation points.
Critical Dotanoc PET Scan Preparation: Somatostatin Analogue Hold
This is the most important preparation requirement unique to Dotanoc scanning. Somatostatin analogues (octreotide, lanreotide) compete with the DOTA-NOC radioligand for somatostatin receptor binding sites. If they are not withheld before the scan, they can significantly reduce tumour uptake of the radiotracer and produce false-negative or artificially low-SUV results — directly impairing PRRT eligibility assessment and staging accuracy.
- Short-acting octreotide (Sandostatin): Withhold for 24 hours before the scan
- Long-acting depot somatostatin analogues (Sandostatin LAR, Somatuline Autogel/Depot): Scan should be performed ideally 4–6 weeks after the last injection, at the trough of drug effect — typically just before the next scheduled injection is due
- Discuss with your oncologist before making any changes to your SSA schedule, as disease breakthrough symptoms may occur during the washout period in symptomatic carcinoid syndrome patients
Failure to adhere to the SSA hold is one of the most common causes of suboptimal Dotanoc PET scan quality. Our team will confirm this preparation requirement with every booking. If there is clinical concern about disease flare during SSA cessation, we can arrange appropriate medical supervision or in-patient scanning. [Insert Internal Link to Dotanoc Preparation Instructions PDF Download]
General Dotanoc PET Scan Preparation
- Fasting: Fast for 4–6 hours before injection. Water is permitted.
- Hydration: Drink 500 mL of water in the 1–2 hours before arrival.
- Duration: Allow 2.5–3 hours total for the appointment.
- Diabetic patients: Standard blood glucose management applies. Our team will provide specific guidance.
- Clothing: Loose, comfortable clothing without metal. Remove jewellery.
Interpreting Dotanoc PET Scan Results: Understanding Your Report
Dotanoc PET/CT reports from Neurad Diagnostics are structured using international consensus reporting standards to provide clinically actionable information for NET multidisciplinary teams. Each report documents the following: primary tumour site, size, and SSTR expression (SUVmax); regional lymph node status; hepatic metastatic burden (number, distribution, size, and SUVmax); bone metastases (sclerotic vs. lytic vs. mixed, with SUVmax); extra-hepatic abdominal and pelvic disease; thoracic involvement; and a summary of overall tumour burden and PRRT suitability assessment.
Reports are co-reported with the low-dose CT component to provide integrated anatomical and functional assessment. Where clinically relevant, we can provide quantitative tumour burden metrics (total lesion volume, total somatostatin receptor expression) for use in clinical trial enrolment and treatment response assessment. Our nuclear medicine physicians are available for direct clinician-to-clinician consultation on complex or clinically urgent Dotanoc scan results. [Insert Internal Link to Contact / Referral Consultation Page]
Dotanoc PET Scan vs. FDG PET/CT for NETs: Complementary Rather Than Competitive
An important nuance in NET imaging is the relationship between Dotanoc PET/CT and FDG PET/CT. Well-differentiated, low-grade NETs (G1 and G2, Ki-67 below 20%) are characteristically SSTR-positive and FDG-negative — making Dotanoc the appropriate scan in these patients. Poorly differentiated neuroendocrine carcinomas (G3, Ki-67 above 55%), however, commonly lose SSTR expression while acquiring high FDG avidity — making FDG PET/CT the preferred modality in this setting.
The “flip-flop phenomenon” — where a tumour is high on one scan and low on the other — carries direct prognostic implications: high FDG avidity with low Dotanoc uptake indicates high-grade disease with a more aggressive clinical course and lower likelihood of PRRT response. For intermediate-grade NETs (G2, Ki-67 10–55%) and discordant clinical situations, performing both Dotanoc and FDG PET/CT provides the most complete biological characterisation and is increasingly recommended by expert NET centres. Neurad Diagnostics can co-ordinate dual PET/CT imaging on the same or sequential days where clinically indicated.
Frequently Asked Questions: Dotanoc PET Scan
How long after my last Sandostatin injection can I have a Dotanoc PET scan?
For long-acting depot preparations (Sandostatin LAR, Somatuline Autogel), the ideal timing is 4–6 weeks after the last injection — at the pharmacodynamic trough, just before the next dose would be due. This maximises receptor availability for the Dotanoc radioligand and ensures optimal scan sensitivity. For short-acting octreotide, a 24-hour hold is sufficient.
Will the Dotanoc scan change my treatment?
For a significant proportion of NET patients, yes. Studies report that Dotanoc PET/CT changes the management plan in 20–40% of NET patients compared to what would have been decided based on conventional CT/MRI alone. This includes upgrading from palliative to curative intent surgery, identifying previously unknown metastases that preclude resection, confirming PRRT eligibility, and identifying disease sites suitable for ablative therapy.
Is a Dotanoc scan the same as an OctreoScan?
OctreoScan (111In-pentetreotide scintigraphy/SPECT) was the predecessor somatostatin receptor imaging agent and has largely been replaced by 68Ga Dotanoc PET/CT. While both target somatostatin receptors, 68Ga Dotanoc PET/CT has dramatically superior resolution (4–5 mm vs. 15–20 mm), shorter examination time (1–2 hours vs. 24 hours), lower radiation dose, and higher sensitivity and specificity. At Neurad Diagnostics, we exclusively perform 68Ga Dotanoc PET/CT and do not offer OctreoScan, as it is no longer considered standard of care for NET imaging.
Why Neurad Diagnostics Is the Specialist Choice for Dotanoc PET Scans
Dotanoc PET/CT is a technically demanding examination that requires not only a functioning 68Ga Gallium Generator and PET/CT scanner, but a nuclear medicine reporting team that understands the complexity of NET biology, the nuances of somatostatin receptor expression, and the clinical implications of the imaging findings for PRRT selection and multidisciplinary team decision-making. At Neurad Diagnostics, we have invested in building exactly this capability — bringing together in-house radiopharmaceutical production, high-performance PET/CT instrumentation, and specialist nuclear medicine expertise under one roof.
For NET patients, receiving their Dotanoc PET scan at a centre with genuine subspecialty expertise — rather than a general nuclear medicine facility performing the investigation occasionally — means a materially higher likelihood of an accurate, complete, and clinically actionable result. This is our commitment at Neurad Diagnostics. Contact us today to discuss your patient’s Dotanoc PET/CT requirements. [Insert Internal Link to Contact Page] [Insert Internal Link to NET Services Page]